FCRL6 receptor: Expression and associated proteins

Immunology Letters

Volumn 134, Issue 2, 2011, Pages 174-182

  Kulemzin, Sergey V ^a   Zamoshnikova, Alina Y ^b   Yurchenko, Mariya Y ^b   Vitak, Nazarii Y ^b   Najakshin, Alexander M ^a   Fayngerts, Svetlana A ^a   Chikaev, Nikolai A ^a   Reshetnikova, Evdokiya S ^a   Kashirina, Natalia M ^c   Peclo, Mikhail M ^c   Rutkevich, Pavel N ^c   Shevelev, Alexander Y ^c   Yanushevskaya, Elena V ^c   Baranov, Konstantin O ^a   Mamonkin, Maksim ^d   Vlasik, Tatjana N ^c   Sidorenko, Svetlana P ^b   Taranin, Alexander V ^a   Mechetina, Ludmila V ^a  

^a INSTITUTE OF CHEMICAL BIOLOGY AND FUNDAMENTAL MEDICINE   (Russian Federation)

^b R E KAVETSKY INSTITUTE OF EXPERIMENTAL PATHOLOGY   (Ukraine)

^c Mona Ltd   (Russian Federation)

^d BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

CD8 T cells; Cellular immunity; FcR like proteins; ITIM; NK cells

Indexed keywords

CD56 ANTIGEN; FC RECEPTOR; FC RECEPTOR LIKE 6 PROTEIN; GROWTH FACTOR RECEPTOR BOUND PROTEIN 2; MESSENGER RNA; PHOSPHOPROTEIN PHOSPHATASE; PROTEIN SHIP 1; PROTEIN SHIP 2; PROTEIN TYROSINE PHOSPHATASE SHP 1; PROTEIN TYROSINE PHOSPHATASE SHP 2; UNCLASSIFIED DRUG;

ADULT; ARTICLE; AUTOIMMUNE DISEASE; BLOOD DISEASE; CD8+ T LYMPHOCYTE; CELL LINEAGE; CELL STIMULATION; CELL SURFACE; CONTROLLED STUDY; ENZYME PHOSPHORYLATION; FLUORESCENCE ACTIVATED CELL SORTING; GENE EXPRESSION REGULATION; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOMODULATION; IN VITRO STUDY; LYMPHOCYTE DIFFERENTIATION; MITOGENESIS; MOLECULAR WEIGHT; NATURAL KILLER CELL; PERIPHERAL LYMPHOCYTE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; RECEPTOR DOWN REGULATION; RECEPTOR UPREGULATION; T LYMPHOCYTE ACTIVATION; WESTERN BLOTTING;

ALTERNATIVE SPLICING; AMINO ACID SEQUENCE; AUTOIMMUNE DISEASES; BLOOD CELLS; CARRIER PROTEINS; CD8-POSITIVE T-LYMPHOCYTES; GENE EXPRESSION REGULATION; HEMATOLOGIC DISEASES; HUMANS; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; KILLER CELLS, NATURAL; MOLECULAR SEQUENCE DATA; RECEPTORS, CELL SURFACE; RNA, MESSENGER; SEQUENCE ALIGNMENT; SPLEEN;

EID: 78650290491     PISSN: 01652478     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.imlet.2010.09.023     Document Type: Article

References (61)

1. Yokoyama W.M., Plougastel B.F. Immune functions encoded by the natural killer gene complex. Nat Rev Immunol 2003, 3:304-316.
2. Moretta L., Bottino C., Pende D., Mingari M.C., Biassoni R., Moretta A. Human natural killer cells: their origin, receptors and function. Eur J Immunol 2002, 32:1205-1211.
3. Lanier L.L. NK cell receptors. Annu Rev Immunol 1998, 16:359-393.
4. Middleton D., Curran M., Maxwell L. Natural killer cells and their receptors. Transpl Immunol 2002, 10:147-164.
5. Zinkernagel R.M., Bachmann M.F., Kundig T.M., Oehen S., Pirchet H., Hengartner H. On immunological memory. Annu Rev Immunol 1996, 14:333-367.
6. Lanzavecchia A., Sallusto F. Dynamics of T lymphocyte responses: intermediates, effectors, and memory cells. Science 2000, 290:92-97.
7. van der Merwe P.A., Davis S.J. Molecular interactions mediating T cell antigen recognition. Annu Rev Immunol 2003, 21:659-684.
8. Sprent J., Surh C.D. T cell memory. Annu Rev Immunol 2002, 20:551-579.
9. Kaech S.M., Wherry E.J., Ahmed R. Effector and memory T-cell differentiation: implications for vaccine development. Nat Rev Immunol 2002, 2:251-262.
10. Kaech S.M., Hemby S., Kersh E., Ahmed R. Molecular and functional profiling of memory CD8 T cell differentiation. Cell 2002, 111:837-851.
11. Liu K., Catalfamo M., Li Y., Henkart P.A., Weng N.P. IL-15 mimics T cell receptor crosslinking in the induction of cellular proliferation, gene expression, and cytotoxicity in CD8+ memory T cells. Proc Natl Acad Sci U.S.A. 2002, 99:6192-6197.
12. Obata-Onai A., Hashimoto S., Onai N., Kurachi M., Nagai S., Shizuno K., et al. Comprehensive gene expression analysis of human NK cells and CD8+ T lymphocytes. Int Immunol 2002, 14:1085-1098.
13. Xu M.J., Zhao R., Zhao Z.J. Molecular cloning and characterization of SPAP1, an inhibitory receptor. Biochem Biophys Res Commun 2001, 280:768-775.
14. Miller I., Hatzivassiliou G., Cattoretti G., Mendelsohn C., Dalla-Favera R. IRTAs: a new family of immunoglobulinlike receptors differentially expressed in B cells. Blood 2002, 99:2662-2669.
15. Davis R.S., Wang Y.H., Kubagawa H., Cooper M.D. Identification of a family of Fc receptor homologs with preferential B cell expression. Proc Natl Acad Sci U.S.A. 2001, 98:9772-9777.
16. Nakayama Y., Weissman S.M., Bothwell A.L. BXMAS1 identifies a cluster of homologous genes differentially expressed in B cells. Biochem Biophys Res Commun 2001, 285:830-837.
17. Guselnikov S.V., Ershova S.A., Mechetina L.V., Najakshin A.M., Volkova O.Y., Alabyev B.Y., et al. A family of highly diverse human and mouse genes structurally links leukocyte FcR, gp42 and PECAM-1. Immunogenetics 2002, 54:87-95.
18. Davis R.S. Fc receptor-like molecules. Annu Rev Immunol 2007, 25:525-560.
19. Maltais L.J., Lovering R.C., Taranin A.V., Colonna M., Ravetch J.V., Dalla-Favera R., et al. New nomenclature for Fc receptor-like molecules. Nat Immunol 2006, 7(5):431-432.
20. Ershova S.A., Naiakshin A.M., Mechetina L.V., Peklo M.M., Shevelev AIa, Vlasik T.N., et al. Expression patterns of the human and mouse IFGP family genes. Mol Biol (Mosk) 2005, 39:776-785.
21. Ehrhardt G.R., Davis R.S., Hsu J.T., Leu C.M., Ehrhardt A., Cooper M.D. The inhibitory potential of Fc receptor homolog 4 on memory B cells. Proc Natl Acad Sci U.S.A. 2003, 100:13489-13494.
22. Leu C.M., Davis R.S., Gartland L.A., Fine W.D., Cooper M.D. FcRH1: an activation coreceptor on human B cells. Blood 2005, 105:1121-1126.
23. Won W.J., Foote J.B., Odom M.R., Pan J., Kearney J.F., Davis R.S. Fc receptor homolog 3 is a novel immunoregulatory marker of marginal zone and B1 B cells. J Immunol 2006, 177:6815-6823.
24. Haga C.L., Ehrhardt G.R., Boohaker R.J., Davis R.S., Cooper M.D. Fc receptor-like 5 inhibits B cell activation via SHP-1 tyrosine phosphatase recruitment. Proc Natl Acad Sci U.S.A. 2007, 104:9770-9775.
25. Wilson T.J., Presti R.M., Tassi I., Overton E.T., Cella M., Colonna M. FcRL6, a new ITIM-bearing receptor on cytolytic cells, is broadly expressed by lymphocytes following HIV-1 infection. Blood 2007, 109:3786-3793.
26. Schreeder D.M., Pan J., Li F.J., Vivier E., Davis R.S. FCRL6 distinguishes mature cytotoxic lymphocytes and is upregulated in patients with B-cell chronic lymphocytic leukemia. Eur J Immunol 2008, 38:3159-3166.
27. Lymphocytes. A practical approach 1987, IRL Press, Oxford. G.G.B. Klaus (Ed.).
28. Sieber G., Bochert G., Enders B., Ruhl H. Characteristics of immunoglobulin secretion in man evaluated by a reverse hemolytic plaque assay. Blut 1980, 41:81-92.
29. Sarkar G., Sommer S.S. The megaprimer method of site-directed mutagenesis. Biotechniques 1990, 8:404-407.
30. Mikhalap S.V., Shlapatska L.M., Berdova A.G., Law C.L., Clark E.A., Sidorenko S.P. CDw150 associates with src-homology 2-containing inositol phosphatase and modulates CD95-mediated apoptosis. J Immunol 1999, 162(10):5719-5727.
31. Harris D.T., Schumacher M.J., Locascio J., Besencon F.J., Olson G.B., DeLuca D., et al. Phenotypic and functional immaturity of human umbilical cord blood T lymphocytes. Proc Natl Acad Sci U.S.A. 1992, 89:10006-10010.
32. Teague T.K., Hildeman D., Kedl R.M., Mitchell T., Rees W., Schaefer B.C., et al. Activation changes the spectrum but not the diversity of genes expressed by T cells. Proc Natl Acad Sci U.S.A. 1999, 96:12691-12696.
33. Cham C.M., Xu H., O'Keefe J.P., Rivas F.V., Zagouras P., Gajewski T.F. Gene array and protein expression profiles suggest post-transcriptional regulation during CD8+ T cell differentiation. J Biol Chem 2003, 278:17044-17052.
34. He X.-S., Greenberg H.B. CD8+ T-cell response against hepatitis C virus. Viral Immunol 2002, 15:121-131.
35. Van Lier R.A.W., ten Berge I.J.M., Garmadia L.E. Human CD8+ T-cell differentiation in response to viruses. Nat Rev Immunol 2003, 3:931-939.
36. Wherry E.J., Ahmed R. Memory CD8 T-cell differentiation during viral infection. J Virol 2004, 78:5535-5545.
37. Phillips J.H., Gumperz J.E., Parham P., Lanier L.L. Superantigen-dependent, cell-mediated cytotoxicity inhibited by MHC class I receptors on T lymphocytes. Science 1995, 268:403-405.
38. Mingari M.C., Schiavetti F., Ponte M., Vitale C., Maggi E., Romagnani S., et al. Human CD8+ T lymphocyte subsets that express HLA class I-specific inhibitory receptors represent oligoclonally or monoclonally expanded cell populations. Proc Natl Acad Sci U.S.A. 1996, 93:12433-12438.
39. Huard B., Karlsson L. KIR expression on self-reactive CD8+ T cells is controlled by T-cell receptor engagement. Nature 2000, 403:325-328.
40. Mingari M.C., Moretta A., Moretta L. Regulation of KIR expression in human T cells: a safety mechanism that may impair protective T-cell responses. Immunol Today 1998, 19:153-157.
41. Young N.T., Uhrberg M. KIR expression shapes cytotoxic repertoires:a developmental program of survival. Trends Immunol 2002, 23:71-75.
42. Anfossi N., Pascal V., Vivier E., Ugolini S. Biology of T memory type 1 cells. Immunol Rev 2001, 181:269-278.
43. Kuo C.T., Veselits M.L., Leiden J.M. LKLF: A transcriptional regulator of single-positive T cell quiescence and survival. Science 1997, 277:1986-1990.
44. Tzachanis D., Freeman G.J., Hirano N., van Puijenbroek A.A., Delfs M.W., Berezovskaya A., et al. Tob is a negative regulator of activation that is expressed in anergic and quiescent T cells. Nat Immunol 2001, 2:1174-1182.
45. Isoda A., Yokohama A., Matsushima T., Tsukamoto N., Nojima Y., Karasawa M. The naive T-lymphocyte compartment is well preserved in patients with chronic myelogenous leukaemia in chronic phase. Br J Haematol 2002, 119:949-955.
46. Guarini A., Breccia M., Montefusco E., Petti M.C., Zepparoni A., Vitale A., et al. Phenotypic and functional characterization of the host immune compartment of chronic myeloid leukaemia patients in complete haematological remission. Br J Haematol 2001, 113:136-142.
47. Buggins A.G., Milojkovic D., Arno M.J., Lea N.C., Mufti G.J., Thomas N.S., et al. Microenvironment produced by acute myeloid leukemia cells prevents T cell activation and proliferation by inhibition of NF-κB, c-Myc, and pRb pathways. J Immunol 2001, 167:6021-6030.
48. Orleans-Lindsay J.K., Barber L.D., Prentice H.G., Lowdell M.W. Acute myeloid leukaemia cells secrete a soluble factor that inhibits T and NK cell proliferation but not cytolytic function-implications for the adoptive immunotherapy of leukaemia. Clin Exp Immunol 2001, 126:403-411.
49. Costello R.T., Sivori S., Marcenaro E., Lafage-Pochitaloff M., Mozziconacci M.J., Reviron D., et al. Defective expression and function of natural killer cell-triggering receptors in patients with acute myeloid leukemia. Blood 2002, 99:3661-3667.
50. Pierson B.A., Miller J.S. CD56+bright and CD56+dim natural killer cells in patients with chronic myelogenous leukemia progressively decrease in number, respond less to stimuli that recruit clonogenic natural killer cells, and exhibit decreased proliferation on a per cell basis. Blood 1996, 88:2279-2287.
51. Chen X., Woiciechowsky A., Raffegerst S., Schendel D., Kolb H.J., Roskrow M. Impaired expression of the CD3-zeta chain in peripheral blood T cells of patients with chronic myeloid leukaemia results in an increased susceptibility to apoptosis. Br J Haematol 2000, 111:817-825.
52. Keystone E.C., Poplonski L., Snow K.M., Martell M. Impaired autologous mixed lymphocyte reaction (AMLR) reactivity of peripheral blood T cell subsets in rheumatoid arthritis. Clin Exp Immunol 1989, 78:184-188.
53. Filaci G., Bacilieri S., Fravega M., Monetti M., Contini P., Ghio M., et al. Impairment of CD8+ T suppressor cell function in patients with active systemic lupus erythematosus. J Immunol 2001, 166:6452-6457.
54. Neumann H., Medana I.M., Bauer J., Lassmann H. Cytotoxic T lymphocytes in autoimmune and degenerative CNS diseases. Trends Neurosci 2002, 25:313-319.
55. Liu F., Wu C., Yang X., Xiao H., Zhuo X., Cheng Z., et al. Polarization and apoptosis of T Cell subsets in idiopathic thrombocytopenic purpura. Cell Mol Immunol 2005, 2:387-392.
56. Ahmadzadeh M., Johnson L.A., Heemskerk B., Wunderlich J.R., Dudley M.E., White D.E., et al. Tumor antigen-specific CD8 T cells infiltrating the tumor express high levels of PD-1 and are functionally impaired. Blood 2009, 114:1537-1544.
57. Fourcade J., Kudela P., Sun Z., Shen H., Land S.R., Lenzner D., et al. PD-1 is a regulator of NY-ESO-1-specific CD8+ T cell expansion in melanoma patients. J Immunol 2009, 182:5240-5249.
58. Day C.L., Kaufmann D.E., Kiepiela P., Brown J.A., Moodley E.S., Reddy S., et al. PD-1 expression on HIV-specific T cells is associated with T-cell exhaustion and disease progression. Nature 2006, 443:350-354.
59. Maier H., Isogawa M., Freeman G.J., Chisari F.V. PD-1:PD-L1 interactions contribute to the functional suppression of virus-specific CD8+ T lymphocytes in the liver. J Immunol 2007, 178:2714-2720.
60. Bengsch B., Seigel B., Ruhl M., Timm J., Kuntz M., Blum H.E., et al. Coexpression of PD-1, 2B4, CD160 and KLRG1 on exhausted HCV-specific CD8+ T cells is linked to antigen recognition and T cell differentiation. PLoS Pathog 2010, 6:e1000947.
61. Schreeder D.M., Cannon J.P., Wu J., Li R., Shakhmatov M.A., Davis R.S. Cutting edge: FcR-like 6 is an MHC class II receptor. J Immunol 2010, 185:23-27.